{"id":760455,"date":"2025-09-01T13:24:01","date_gmt":"2025-09-01T13:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=760455"},"modified":"2025-09-01T13:24:01","modified_gmt":"2025-09-01T13:24:01","slug":"neuroendocrine-tumors-pipeline-analysis-2025-by-delveinsight-rayzebio-inc-camurus-vyriad-inc-adc-therapeutics-eli-lilly-and-company-biotheus-inc-immunitybio-inc-chimerix-merck-sharp","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-tumors-pipeline-analysis-2025-by-delveinsight-rayzebio-inc-camurus-vyriad-inc-adc-therapeutics-eli-lilly-and-company-biotheus-inc-immunitybio-inc-chimerix-merck-sharp_760455.html","title":{"rendered":"Neuroendocrine tumors Pipeline Analysis, 2025 by DelveInsight | RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1756732615.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neuroendocrine tumors Pipeline Analysis, 2025 by DelveInsight | RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp \" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1756732615.jpg\" alt=\"Neuroendocrine tumors Pipeline Analysis, 2025 by DelveInsight | RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Neuroendocrine tumors Pipeline Analysis<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cNeuroendocrine Tumors- Pipeline Insight, 2025\u201d report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight reports that the Neuroendocrine Tumors (NET) pipeline involves over 100 key companies actively developing more than 120 therapeutic candidates.<\/p>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Neuroendocrine cancer, also called a neuroendocrine tumor (NET) or neuroendocrine neoplasm, arises from specialized cells of the neuroendocrine system, which exhibit traits of both hormone-secreting endocrine cells and nerve cells. These cells are found throughout the body and play a vital role in regulating various physiological processes. Hormones produced by these cells act as chemical messengers, traveling through the bloodstream to affect the function of organs or cells. NETs typically grow slowly, often taking years to develop.<\/p>\n<p style=\"text-align: justify;\">NETs are categorized as functional or nonfunctional depending on their hormone secretion. Functional NETs produce excess hormones, whereas nonfunctional NETs either secrete none or produce amounts too low to trigger noticeable symptoms. The specific hormone produced depends on the tumor&rsquo;s location in the body. According to the American Society of Clinical Oncology (ASCO), roughly 60% of NETs are nonfunctional. Whether a NET is functional significantly affects both the symptoms experienced and the treatment strategy.<\/p>\n<p style=\"text-align: justify;\">NETs are often discovered for various reasons since they usually do not cause a consistent set of symptoms. In early stages, they are often asymptomatic and may be found incidentally during imaging or surgery for unrelated conditions. When symptoms do appear, they are typically related to the tumor&rsquo;s size, location, or hormone production, as seen in cases such as carcinoid syndrome.<\/p>\n<p style=\"text-align: justify;\"><strong>Download our report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Neuroendocrine tumors Pipeline Insight 2025&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Neuroendocrine tumors Therapeutics Market.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Neuroendocrine tumors Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s report on the Neuroendocrine Tumors (NET) pipeline highlights a vibrant landscape, with over 100 companies actively developing more than 120 therapeutic candidates for NET treatment.<\/p>\n<\/li>\n<li>\n<p>In December 2024, the FDA approved CRENESSITY&trade; (crinecerfont) from Neurocrine Biosciences for the treatment of classic congenital adrenal hyperplasia (CAH). While CAH is not a neuroendocrine tumor, this milestone underscores continued progress in endocrine-related therapies.<\/p>\n<\/li>\n<li>\n<p>Leading companies advancing NET treatments include RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp &amp; Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, and others.<\/p>\n<\/li>\n<li>\n<p>Notable NET pipeline therapies in various stages of development include RYZ101, CAM2029, Ramucirumab, Voyager-V1, ADCT-701, among several additional candidates.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The Neuroendocrine tumors pipeline insights report 2025, provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Provides comprehensive insights into key companies developing therapies in the Neuroendocrine tumors Market.<\/p>\n<\/li>\n<li>\n<p>Categorizes Neuroendocrine tumors therapeutic companies by development stage: early, mid, and late-stage.<\/p>\n<\/li>\n<li>\n<p>Highlights major companies involved in targeted therapy development, including both active and inactive (paused\/discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Reviews emerging Neuroendocrine tumors drugs under development based on:<\/p>\n<ul>\n<li>\n<p>Stage of development<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Route of administration<\/p>\n<\/li>\n<li>\n<p>Target receptor<\/p>\n<\/li>\n<li>\n<p>Monotherapy vs. combination therapy<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Mechanism of action<\/p>\n<\/li>\n<li>\n<p>Molecular type<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Offers detailed analysis of:<\/p>\n<ul>\n<li>\n<p>Company-to-company and company-academia collaborations<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Licensing agreements<\/p>\n<\/li>\n<li>\n<p><strong>Funding and investment activities supporting future Neuroendocrine tumors market advancement.<\/strong><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request for a sample report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>RYZ101: RayzeBio, Inc.<\/p>\n<\/li>\n<li>\n<p>CAM2029: Camurus<\/p>\n<\/li>\n<li>\n<p>Ramucirumab: Eli Lilly and Company<\/p>\n<\/li>\n<li>\n<p>Voyager-V1: Vyriad, Inc.<\/p>\n<\/li>\n<li>\n<p>ADCT-701: ADC Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">More than 100 leading companies are actively developing therapies for neuroendocrine tumors, with RayzeBio, Inc. advancing a drug candidate to the most advanced stage&mdash;Phase III clinical trials.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 120+ products under different phases of Neuroendocrine tumors clinical trials like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Neuroendocrine tumors Late stage Therapies (Phase III)<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Mid-stage Therapies (Phase II)<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Early-stage Therapies (Phase I)<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Pre-clinical and Neuroendocrine tumors Discovery stage Therapies<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine tumors Discontinued &amp; Inactive Therapies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors pipeline report provides the Neuroendocrine tumors therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Neuroendocrine tumors Therapies and Key Neuroendocrine tumors Companies: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Neuroendocrine tumors Clinical Trials and recent advancements<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Neuroendocrine tumors Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Neuroendocrine tumors Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">&bull; Neuroendocrine tumors By Stage<\/p>\n<p style=\"text-align: justify;\">&bull; Neuroendocrine tumors Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">&bull; Neuroendocrine tumors Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\"><strong>Download Neuroendocrine tumors Sample report to know in detail about the Neuroendocrine tumors treatment market @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Neuroendocrine tumors Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Neuroendocrine tumors Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Neuroendocrine tumors &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Neuroendocrine tumors Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Neuroendocrine tumors Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Neuroendocrine tumors Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Neuroendocrine tumors Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Neuroendocrine tumors Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Neuroendocrine tumors Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Neuroendocrine tumors Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Neuroendocrine tumors Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Neuroendocrine tumors Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get Detailed Insights About the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Neuroendocrine tumors Pipeline Reports Offerings<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neuroendocrine-tumors-pipeline-analysis-2025-by-delveinsight-rayzebio-inc-camurus-vyriad-inc-adc-therapeutics-eli-lilly-and-company-biotheus-inc-immunitybio-inc-chimerix-merck-sharp\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neuroendocrine-tumors-pipeline-analysis-2025-by-delveinsight-rayzebio-inc-camurus-vyriad-inc-adc-therapeutics-eli-lilly-and-company-biotheus-inc-immunitybio-inc-chimerix-merck-sharp\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neuroendocrine tumors Pipeline Analysis DelveInsight\u2019s, \u201cNeuroendocrine Tumors- Pipeline Insight, 2025\u201d report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-tumors-pipeline-analysis-2025-by-delveinsight-rayzebio-inc-camurus-vyriad-inc-adc-therapeutics-eli-lilly-and-company-biotheus-inc-immunitybio-inc-chimerix-merck-sharp_760455.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-760455","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/760455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=760455"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/760455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=760455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=760455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=760455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}